Status:
NOT_YET_RECRUITING
BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry
Lead Sponsor:
University Hospital, Lille
Conditions:
Rhinosinusitis Chronic
Nasal Polyps
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So fa...
Eligibility Criteria
Inclusion
- Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval.
- The patients already treated according to this criteria since August 2021 will be followed and their previous clinical and biological data retrospectively collected
Exclusion
- Oral corticotherapy in the previous month;
- Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months of initiation of treatment apart from ongoing biotherapies for severe asthma or CRSwNP;
- Hypersensitivity to humanized antibodies ;
- Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;
- Pregnant or breast-feeding women;
- Patient without social coverage.
Key Trial Info
Start Date :
September 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 2 2035
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06501807
Start Date
September 2 2024
End Date
January 2 2035
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Lille
Lille, France